News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Veradermics Reports First Positive Efficacy in Women for Hair Loss Treatment
Veradermics reported positive results for its oral formulation of minoxidil to treat female pattern hair loss.
Biogen Reports Early Success from Apellis Acquisition
Since Biogen’s acquisition of Apellis in May 2026, the company’s C3 complement therapies, Syfovre® and Empaveli®, have generated a combined $128 million in revenues.
Nia Therapeutics Develops Breakthrough Device to Restore Memory
The device is based on technology developed at Penn by Dr. Kahana and Dr. Rizzuto.
Kira Pharmaceuticals to Merge with Jasper Therapeutics in a Deal Backed by $132M to Advance Immune Disease Pipeline
Jasper Therapeutics recently completed its merger with Kira Pharmaceuticals.
New mRNA Vaccine Could Reduce the Recurrence and Spread of Skin Cancer
Moderna and Merck announced a successful late-stage trial for a personalized mRNA vaccine designed to help prevent the return and spread of melanoma.
Press Highlights of FY26
During the 2025 fiscal year, there were 119 press mentions for PCI-supported programs, startups and partners. Some of the most popular and widely circulated stories are included here.
Penn I-Corps Fall 2025 Cohort Completes Program
Read about the 2025 participants.
(Co)nnect: Philly’s AI Ecosystem Summit at Pennovation Works
On May 7, 2026, Pennovation Works hosted (Co)nnect: Philly's AI Ecosystem Summit.
Pennovation Accelerator’s Pitch Day 2025
The Pennovation Accelerator held its eighth annual Pitch Day on July 23, 2025, the final event for the cohort's six-week program focused on business development.
Penn Robotics Technology Spotlight
These technologies focus on developing innovative solutions to improve healthcare, engineering, and everyday life.